Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
Status:
NOT_YET_RECRUITING
Trial end date:
2032-02-28
Target enrollment:
Participant gender:
Summary
The purpose of the present Phase 3 trial is to confirm the efficacy and safety of glepaglutide 10 mg twice weekly in a patient population with SBS-IF and generate additional long-term safety data.
Glepaglutide is the International Nonproprietary Name and United States Adopted Name (USAN) for ZP1848.